PB
PBMWW
PSYENCE BIOMEDICAL LTD.
$0.0205
+2.50%
$63.5K
No data for this timeframe.
Vol
Market Cap$63.5K
Cap SizeNano Cap
Inst. Holders1 funds
Inst. Value$11.00
SEC Reports3
Recent Activity
Apr 23, 2026
SEC
Psyence Biomedical Ltd. has initiated patient dosing in its Phase IIb clinical trial evaluating NPX-5, a GMP-compliant,
6-K — Impact 7/10
Apr 20, 2026
SEC
Psyence Biomedical Ltd. amended its existing stock purchase agreement with White Lion Capital to introduce a new 'Intrad
6-K — Impact 6/10
Apr 20, 2026
short_volume
Short Volume: PBMWW — 69.6% short (0.3M / 0.5M)
Short: 349,636 | Exempt: 51,732 | TRF Vol: 501,996 | Short Ratio: 69.6% | Off-exchange volume (dark
Apr 17, 2026
SEC
Psyence Biomedical issued a press release welcoming anticipated U.S. executive action to advance research into ibogaine,
6-K — Impact 4/10
Latest Reports
BULLISH
6-K
7/10
Psyence Biomedical Ltd. has initiated patient dosing in its Phase IIb clinical trial evaluating NPX-5, a GMP-compliant,
Apr 23, 2026
BEARISH
6-K
6/10
Psyence Biomedical Ltd. amended its existing stock purchase agreement with White Lion Capital to introduce a new 'Intrad
Apr 20, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| UBS Group AG | $11.00 | — |
1 institutional holders with $11.00 total value (455 shares) as of 2025-Q3. Top holders: UBS.
Top Institutional Holders — 2025-Q3
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | UBS Group AG | 455 | $11.00 | 100.0% | — |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 5.7/10.
BULLISH
6-K
7/10
Psyence Biomedical Ltd. has initiated patient dosing in its Phase IIb clinical trial evaluating NPX-
Apr 23, 2026
BEARISH
6-K
6/10
Psyence Biomedical Ltd. amended its existing stock purchase agreement with White Lion Capital to int
Apr 20, 2026
NEUTRAL
6-K
4/10
Psyence Biomedical issued a press release welcoming anticipated U.S. executive action to advance res
Apr 17, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Apr 20, 2026
short_volume
Short Volume: PBMWW — 69.6% short (0.3M / 0.5M)
Short: 349,636 | Exempt: 51,732 | TRF Vol: 501,996 | Short Ratio: 69.6% | Off-exchange volume (dark pool + OTC)